# BATCH 65.5 — Completion Report

**Status:** ✅ **CLOSED 2026-04-26 via SKIP route**
**Result:** Phase A0 (market-window control) returned a decisive routing decision: SKIP A/B/C/D, defer to Phase 19.5 AMR. **No code change shipped.** vwap_pullback stays in the strong-trend lane unchanged.
**Scope:** `BATCH_65_5_SCOPE.md` (Step-1 Langston-approved 2026-04-25 with 5 refinements; Phase A0 amendment Step-1 Langston-approved 2026-04-26 with 5 refinements)
**Phase A0 deliverable:** `B65_5_PHASE_A0_WINDOW_CONTROL.md` (commit `a5ff61dc`)
**Trigger:** B63 Item 13 BUILD_DEDICATED verdict (now provisionally reframed as INCONCLUSIVE — see §3 below)
**Workflow lessons:** documented in §5

---

## 1. Outcome summary

The 57-trade vwap_pullback cohort that produced the B63 Item 13 BUILD_DEDICATED verdict was contaminated by a single catastrophic day (2026-04-22) that drove virtually all of the cohort net loss. Sibling-strategy WR in the same ±60min windows was 25.8% (vs. cohort 27.0%), and the lane-mate `strong_bull_trend` was at 23.9% in the same windows. Excluding the 04-22 day, the cohort WR jumps to 43.2% and *outperforms* the lane-mate by ~10 points.

**Strategy quality and window quality could not be separated in the original cohort.** The right action is therefore to:

1. Leave vwap_pullback in the strong-trend lane.
2. Reframe the B63 Item 13 verdict as INCONCLUSIVE — INSUFFICIENT EVIDENCE.
3. Open a future batch (TBD-numbered) to re-evaluate with cleaner, post-Phase-19 paper-mode data.
4. Treat the 04-22 evidence as a canonical positive case for the Phase 19.5 AMR detection layer.

The Adaptive Market Response (Phase 19.5) case is strengthened by the recurrence pattern Langston identified during review: 04-22 is the second instance of the same failure mode as the B63 04-18 streakiness day — both with globalRegime classified as TREND_FRIENDLY_STABLE while the market disagreed catastrophically. Two such days in a single ~5-day window is not a one-off anomaly.

---

## 2. Objectives checklist

| # | Objective | Status | Evidence |
|---|---|---:|---|
| 1 | Step-1 scope drafted with Phase A research-then-design framing | ✅ | `BATCH_65_5_SCOPE.md` |
| 2 | Step-1 scope reviewed + approved by Langston with refinements incorporated | ✅ | cc-inbox #819, scope §8 review log |
| 3 | Methodology improvement: Phase A0 market-window control inserted (Kyle directive 2026-04-26) | ✅ | scope §2 phase order, Phase A0 block |
| 4 | Step-1 amendment approved by Langston with 5 refinements incorporated | ✅ | cc-inbox #820, scope updated |
| 5 | Phase A0 data extracted from VTS JSONL logs (2026-04-21..2026-04-25) | ✅ | `/tmp/a0_phase.py` on staging, 63-trade cohort |
| 6 | Phase A0 sibling-strategy WR control computed | ✅ | A0 doc §2.2 |
| 7 | Phase A0 SBT focused control computed (Langston Q3) | ✅ | A0 doc §2.2 |
| 8 | Phase A0 per-day breakdown (Langston Q5) | ✅ | A0 doc §2.3 |
| 9 | Phase A0 sensitivity (excl. 04-22) | ✅ | A0 doc §2.4 |
| 10 | Phase A0 routing decision per gate matrix | ✅ | A0 doc §3 — ROUTE 2 (SKIP) |
| 11 | Langston review of A0 findings + sign-off on routing | ✅ | cc-inbox #821 — both routing + INCONCLUSIVE reframing approved |
| 12 | Recurrence finding (04-22 = second instance of 04-18 pattern) added (Langston cc-inbox #821) | ✅ | A0 doc §2.2.1 |
| 13 | B63 Item 13 verdict reframed as INCONCLUSIVE | ⏳ | Addendum to be written in same governance commit as this report |
| 14 | Future-batch slot opened for Item 13 reconsideration (Kyle directive 2026-04-26) | ⏳ | MEMORY note added; BATCH_CATALOG slot pending |
| 15 | Phase 19.5 AMR concept doc updated with 04-22 evidence + recurrence pattern | ⏳ | Pending governance commit |
| 16 | Tier 1 + Tier 2 governance updated | ⏳ | This report + addenda + catalog/history updates land in same commit |

**Gate not invoked:** Phases A, B, C, D were NOT run because Phase A0 routed to SKIP. This was the correct workflow behavior and validates the value of inserting A0 ahead of A.

---

## 3. The B63 Item 13 verdict reframe

**Original verdict (BATCH_63_COMPLETION_REPORT.md §11, closed 2026-04-25):** BUILD_DEDICATED. 57 closed trades / 21.1% WR / sumR −28.99 at 2.85× min sample. Both metrics deep below KEEP and TUNE thresholds.

**Reframed verdict (provisional, 2026-04-26):** INCONCLUSIVE — INSUFFICIENT EVIDENCE. The original verdict was procedurally correct and met the pre-registered thresholds on the data available. Phase A0 has since shown that the cohort metrics reflect window-quality contamination rather than strategy-quality failure. The pre-registered thresholds did not include a sibling-strategy WR control to identify hostile-window contamination — that is a methodology gap to land in the future re-evaluation batch, not a flaw in the B63 process.

**Original closure stands as historical record.** The 2026-04-26 addendum to `BATCH_63_COMPLETION_REPORT.md` §11 documents the reframe and the methodology improvement.

**Future re-evaluation batch (number TBD):** opens in MEMORY and BATCH_CATALOG as a queued slot. Earliest cleanly-comparable cohort is post-Phase-19 paper audit, when active trading has run through enough days that we can pull a cohort that does not heavily overlap a single catastrophic window.

---

## 4. Files touched in this batch

**Created:**
- `Claude Comms and Packages/Scope Files/BATCH_65_5_SCOPE.md` (commit `8a18bce4`, amended commit `a5ff61dc`)
- `Claude Comms and Packages/Scope Files/B65_5_PHASE_A0_WINDOW_CONTROL.md` (commit `a5ff61dc`)
- `Claude Comms and Packages/Batch Completion/BATCH_65_5_COMPLETION_REPORT.md` (this file)
- `/tmp/a0_phase.py` on staging (analysis script, preserved on disk)

**Modified in same governance commit as this report:**
- `Claude Comms and Packages/Batch Completion/BATCH_63_COMPLETION_REPORT.md` — 2026-04-26 addendum reframing Item 13 verdict
- `1-system-manual/BATCH_CATALOG.md` — B65.5 row updated to CLOSED via SKIP, B63 row updated with reframe note, new TBD-numbered future-batch slot for Item 13 reconsideration
- `1-system-manual/PHASE_HISTORY.md` — Phase 15c continuation entry for B65.5 closure
- `1-system-manual/ADAPTIVE_MARKET_RESPONSE_CONCEPT.md` — 04-22 + recurrence evidence added as canonical positive case
- `MEMORY.md` — B65.5 closure + Item 13 reframe + future-batch slot

**No code files modified.** This batch ships zero TypeScript / SQL / migration changes.

---

## 5. Workflow lessons (for future research-then-design batches)

1. **Insert market-window controls as a default Phase A0 in any batch triggered by a "negative cohort" verdict.** The B63 Item 13 evaluation was procedurally clean against pre-registered thresholds, but the thresholds didn't account for the streakiness phenomenon that B63 had itself documented. Future decision-gate specs should include sibling-strategy WR controls in the threshold definition, not as a separate phase.

2. **The cost of A0 is cheap; the benefit is preventing wasted code work.** A0 took less than an hour of analysis time and prevented Phases A/B/C/D entirely (which would have been 1–2 weeks of pattern-classification + hypothesis + backtest work, all built on a bad-window-contaminated foundation). Cost-benefit on inserting controls before pattern-work is overwhelmingly favorable.

3. **Recurring failure modes deserve their own architectural response, not strategy-by-strategy detector tweaks.** The 04-18 + 04-22 recurrence pattern is two instances in one week of "globalRegime = TFS while market disagrees catastrophically." The right response is not to fix each affected strategy individually but to build the AMR detection layer that throttles trading when the conditions are detected. Phase 19.5 is the right home for this work.

4. **A negative finding can be the deliverable.** "We found insufficient evidence to redesign the strategy, and we found strong evidence that the original verdict needs reconsideration" is a high-value outcome. B65.5 closes with no code change but with decision-grade clarity on what NOT to do and why.

---

## 6. Governance documents touched

Per CLAUDE.md §3, this completion report lists every governance file modified by B65.5:

**Tier 1 (always):**
- `BATCH_CATALOG.md` — B65.5 row, B63 row reframe note, future-batch slot
- `PHASE_HISTORY.md` — Phase 15c continuation entry
- `MEMORY.md` — closure + reframe + future-batch flag
- `BATCH_65_5_SCOPE.md` — scope (drafted + amended in this batch)
- `BATCH_65_5_COMPLETION_REPORT.md` — this file

**Tier 2 (where applicable):**
- `BATCH_63_COMPLETION_REPORT.md` — 2026-04-26 addendum
- `ADAPTIVE_MARKET_RESPONSE_CONCEPT.md` — 04-22 + recurrence evidence

**Tier 2 NOT touched (and why):**
- `SYSTEM_IMPACT_MAP.md` — no component added/removed/modified
- `SYSTEM_MANUAL.md` — no architecture or math changes
- `CHANGES_AND_FIXES.md` — no bug/risk fix shipped
- `RUNNING_ISSUES.md` — Item 13 reframe doesn't count as a new open issue (the original closure stands; the reframe is documented in B63 completion report)

---

*B65.5 closed 2026-04-26. Phase A0 deliverable + this report are the artifacts. vwap_pullback stays in the strong-trend lane. B63 Item 13 verdict reframed as INCONCLUSIVE pending future re-evaluation batch.*
